International Journal of Methods in Psychiatric Research
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
Published online in Wiley InterScience
(www.interscience.wiley.com) DOI: 10.1002/mpr.256
The Netherlands Study of Depression
and Anxiety (NESDA): rationale, objectives
and methods
BRENDA W.J.H. PENNINX,1,2,3 AARTJAN T.F. BEEKMAN,1 JOHANNES H. SMIT,1 FRANS G. ZITMAN,2
WILLEM A. NOLEN,3 PHILIP SPINHOVEN,4 PIM CUIJPERS,5 PETER J. DE JONG,6
HARM W.J. VAN MARWIJK,7 WILLEM J.J. ASSENDELFT,8 KLAAS VAN DER MEER,9
PETER VERHAAK,10 MICHEL WENSING,11 RON DE GRAAF,12 WITTE J. HOOGENDIJK,1
JOHAN ORMEL,3 RICHARD VAN DYCK1 FOR THE NESDA RESEARCH CONSORTIUM
1 Department of Psychiatry/EMGO Institute/Institute for Neurosciences, VU University Medical Centre,
Amsterdam, The Netherlands
2 Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands
3 Department of Psychiatry, University Medical Centre Groningen, University of Groningen, Groningen,
The Netherlands
4 Department of Clinical Psychology, Leiden University, Leiden, The Netherlands
5 Department of Clinical and Health Psychology, VU University, Amsterdam, The Netherlands
6 Department of Clinical and Developmental Psychology, University of Groningen, The Netherlands
7 Department of General Practice, VU University Medical Centre, Amsterdam, The Netherlands
8 Department of Public Health and Primary Care, Leiden University Medical Centre, Leiden, The
Netherlands
9 Department of General Practice, University Medical Centre Groningen, University of Groningen,
Groningen, The Netherlands
10 Netherlands Institute for Health Services Research, Utrecht, The Netherlands
11 Centre for Quality of Care Research, Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands
12 Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands, for the NESDA
Research Consortium
Abstract
The Netherlands Study of Depression and Anxiety (NESDA) is a multi-site naturalistic cohort study to: (1) describe the
long-term course and consequences of depressive and anxiety disorders, and (2) to integrate biological and psychosocial
research paradigms within an epidemiological approach in order to examine (interaction between) predictors of the longterm course and consequences.
Its design is an eight-year longitudinal cohort study among 2981 participants aged 18 through 65 years. The sample
consists of 1701 persons with a current (six-month recency) diagnosis of depression and/or anxiety disorder, 907 persons
with life-time diagnoses or at risk because of a family history or subthreshold depressive or anxiety symptoms, and 373
healthy controls. Recruitment took place in the general population, in general practices (through a three-stage screening
procedure), and in mental health organizations in order to recruit persons reflecting various settings and developmental
stages of psychopathology. During a four-hour baseline assessment including written questionnaires, interviews, a medical
examination, a cognitive computer task and collection of blood and saliva samples, extensive information was gathered
Copyright © 2008 John Wiley & Sons, Ltd
122
Penninx et al.
about key (mental) health outcomes and demographic, psychosocial, clinical, biological and genetic determinants. Detailed
assessments will be repeated after one, two, four and eight years of follow-up.
The findings of NESDA are expected to provide more detailed insight into (predictors of) the long-term course of
depressive and anxiety disorders in adults. Besides its scientific relevance, this may contribute to more effective prevention
and treatment of depressive and anxiety disorders. Copyright © 2008 John Wiley & Sons, Ltd.
Key words: depressive disorder, anxiety disorder, course, epidemiology, longitudinal studies
Introduction
Depressive and anxiety disorders are common at all
ages. In addition, their effects on well-being and daily
functioning are enormous and comparable to those of
major chronic physical illnesses (Buist-Bouwman et al.,
2006; Murray and Lopex, 1997). In economic terms,
the cost of depressive and anxiety disorders due to loss
of productivity and use of health services ranks among
the top-five of all disorders (Smit et al., 2006). Consequently, depressive and anxiety disorders are relevant
candidates for efforts to improve public health.
During the past decades, progress has been made in
the development and testing of different forms of treatment for depressive and anxiety disorders. Although
successful treatment is available, a large proportion of
those affected remains undiagnosed and untreated (Bijl
and Ravelli, 2000), and treatment is not effective for
everyone. Moreover, although it is firmly established
that the duration of episodes can be influenced with
treatment, it is uncertain whether treatment has effect
on the long-term course of depressive or anxiety disorders. The extremely variable natural history precludes
matching interventions accurately to those who are
most in need of treatment. This is reflected in current
professional treatment guidelines which offer little
guidance as to which patients may recover without
substantial treatment and which patients may be in
need of more intensive interventions. A first requirement for a more accurate matching of limited treatment
resources to the projected need of patients is to have
detailed knowledge of the factors that determine or
predict the prognosis. For this, data on (determinants
of) the long-term course and consequences of anxiety
and depressive disorders are essential.
We are currently conducting the Netherlands Study
of Depression and Anxiety (NESDA), a multi-centre
study designed to examine the long-term course and
consequences of depressive and anxiety disorders. This
paper presents the basic rationales, objectives and
methods of NESDA.
Copyright © 2008 John Wiley & Sons, Ltd
Key rationales
There were four key rationales that guided our design,
which will be discussed.
Rationale 1: Insight into long-term prognosis of depressive
and anxiety disorders is limited
Both in the literature and in clinical practice, the
disease-episode-model for the prognosis of depression
and anxiety dominates. Using this model, the median
duration of episodes of major depressive disorder (MDD)
ranges between 3–6 months, whereas using the prevailing definition of chronicity of MDD (duration > two
years) approximately 20% of episodes becomes chronic
(Keller et al., 1992; Spijker et al., 2002). Nevertheless,
although remission occurs, the course of MDD is typified by recurrences: in a meta-analysis of studies among
depressed patients in psychiatric settings, 76% had one
or more recurrent episodes over 10 years (Piccinelli and
Wilkinson, 1994). Although several studies of the prognosis of MDD are available, the Collaborative Depression Study (CDS) has probably been the most influential.
In this study, 431 adults with MDD who were treated
in academic centres were followed over 12 years. Using
the disease-episode-model, the above figures for duration of episodes were reached (Keller et al., 1992; Keller
at al., 1984). However, using the life-chart method the
prognosis appeared to be pleiomorphic with symptom
levels changing frequently; patients were symptomatically ill in 59% of the weeks over 12 years, much of
which at the minor, dysthymic or subthreshold level
(Judd et al., 1998). Using similar methodology in population-based studies provided rather similar conclusions
indicating that depression is a chronic intermittent disorder in the majority of cases (Judd, 1997). Therefore,
to describe the longitudinal course, the disease-episodemodel for the prognosis of affective disorders should be
complemented with a dimensional model describing
the waxing and waning of symptoms (Duncan-Jones
et al., 1990).
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
Netherlands Study of Depression and Anxiety (NESDA)
For anxiety disorders, the (few) studies examining
the course, have also focused on the disease-episode
model. The Harvard/Brown Anxiety Research programme (HARP) repeatedly assessed 711 psychiatric
outpatients with anxiety disorder (panic, social phobia
or generalized anxiety disorder) at 6 to 12 month intervals over 10 years. The course of anxiety disorders
appeared to be poor with the smallest probability of
recovery for social phobia (Bruce et al., 2005). Only
35% of 232 outpatients with social phobia recovered
during 10 years, whereas the recurrence rate once
recovery was achieved was 34% (Keller, 2006). In two
reviews, it was estimated that the course of panic disorder shows only little to no improvement in 36–40%
of the subjects after 1 to 20 years of treatment (Keller
and Hanks, 1993; Pollack and Otto, 1997). These results
depict anxiety disorders as insidious with low recovery
rates and high recurrence rates, and beg for more naturalistic long-term studies that examine episodes as well
as symptoms in order to improve our knowledge about
the course of anxiety disorders.
Rationale 2: When studying depression and anxiety
disorders, different settings and developmental stages
should be considered
Although common throughout settings, the prevalence
of depressive and anxiety disorders increases as one
moves from the community, through primary care, to
specialized health care settings (Goldberg and Huxley,
1992). Those with the most severe, complex, recurrent
and longstanding disorders are more likely to be referred
to specialized mental health care (Bijl and Ravelli,
2000). The setting in which subjects are recruited is
therefore crucial to the outcome, since those recruited
in specialized mental health care are a selection of
those with the least favourable prognosis. Unfortunately, there are no longitudinal studies that have
included sufficient subjects representative of those suffering from depressive and anxiety disorders in different
health care settings. Studies like HARP and CDS (discussed earlier) provide information on the course of
psychiatric outpatients in specialty clinics, but the
extent to which this information is generalizable to
community and primary care settings – where the
majority of cases resides – needs to be determined.
The clinical developmental stage of a disorder has
shown to be a key determinant of the course of a
depressive or anxiety disorder. This can be best
demonstrated by the importance of previous history,
Copyright © 2008 John Wiley & Sons, Ltd
123
duration and severity of the index episode for the prognosis (Spijker et al., 2002). However, these clinical
factors do not explain the wide variation in the prognosis: it is highly likely that underlying biological and
psychosocial factors, such as genetics or personality,
partly determine both the clinical features of index
episodes and its subsequent course. Patients enrolled in
specialized health care settings generally have a more
progressed developmental stage of their illness than
patients in primary care or community settings (Suh
and Gallo, 1997; Cooper-Patrick et al., 1994). Consequently, clinical setting and developmental stage of the
illness are highly correlated. To obtain a full understanding of the course of depressive and anxiety disorders, it is crucial to design studies that include patients
from different settings and developmental stages of
illness. Such a study would not only allow comparison
of the (prediction of) course between patients from
different settings and developmental stages, but would
also allow for studies of trajectories of care, focusing on
factors determining transitions from informal to different levels of formal care.
Rationale 3: Depressive and anxiety disorders should be
studied in concert
Previous studies have shown that comorbidity among
depressive and anxiety disorders is rule rather than
exception: comorbidity rates range from 30% through
60% (Kessler et al., 1994; Beekman et al., 2000; Angst,
1996; Sartorius et al., 1996; van Balkom et al., 2000;
de Graaf et al., 2002). Depressive and anxiety disorders
often arise sequentially within the same patient: the
order is more likely to start with anxiety, depression
commonly arising later (Merikangas et al., 1996;
de Graaf et al., 2002). Another line of research shows
that patients with both anxiety and depression have
more severe symptoms, more disability, a longer duration of illness and are less likely to respond to treatment
(Vollrath and Angst, 1989; Bijl and Ravelli, 2000;
Hecht and Wittchen, 1990; Roy-Byrne et al., 2000;
Bruce et al., 2005; Ormel et al., 1994). Finally, analyses
of depression and anxiety comorbidity patterns identified a three-dimensional model underlying these diagnoses that distinguished an externalizing domain as
well as an internalizing domain, the latter consisting of
a panic/phobia dimension and an affective dimension
including depression and generalized anxiety disorder
(GAD). (Krueger, 1999; Vollebergh et al. 2001).
Given the debate about the validity of a categorical
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
124
Penninx et al.
distinction between anxiety and depression (Goldberg,
1996), and the undisputed close relationship between
both, a long-term study should examine anxiety and
depression in concert, focusing on comorbidity patterns
and employing both a dimensional and a categorical
approach to the diagnosis of depressive and anxiety
disorders.
Rationale 4: Psychosocial and biological paradigms
should be integrated when examining depressive and
anxiety disorders
Studies suggest that depressive and anxiety disorders
share common risk factors and that similar interventions are effective (Andrews and Stephens, 1990; Brown
et al., 1996; Beekman et al., 2000). With regard to risk
factors, there is some evidence supporting the idea that
depressive and anxiety disorders share longstanding
vulnerability factors, with recent stress factors determining the specific disorder (Kendler et al., 1987;
Goldberg and Huxley, 1992). An interdisciplinary
approach when studying depressive and anxiety disorders is important, since the etiology of these disorders
is likely multi-causal. Etiological studies have yielded
important findings, but single risk factors only explain
modest parts of the etiology. Also for the course of
disorders, it is unlikely that there exists one single predictor. Accurate prediction of the course of depressive
and anxiety disorders requires that psychosocial and
biological research paradigms be integrated within a
common psychiatric epidemiological framework
(Merikangas et al., 2002). The rapid technological
advances such as genomics have recently allowed such
integration which enables research into the interaction
between psychosocial and biological determinants.
Recent examples confirm that these domains interact.
For instance, a serotonin transporter genetic polymorphism influences depressiveness only when stressful life
events are present (Caspi et al., 2003), and hypothalamic-pituitary-adrenal (HPA) axis dysregulation in
depression is most obvious after traumatic childhood
exposure (Heim et al., 2002). These observations have
indicated that interactions between determinants are
likely contributing to depressive and anxiety disorders,
and consequently, may be important as well in determining their course. Ideally, future psychiatric epidemiological studies should be designed to integrate
psychosocial and biological paradigms and should
be large enough to allow exploration of interaction
between domains.
Copyright © 2008 John Wiley & Sons, Ltd
Objectives
In line with the rationales mentioned earlier, NESDA
was designed as a naturalistic, longitudinal cohort
study including respondents from different health care
settings (community, primary care and specialized
mental health care) and in different stages of the developmental history of disorders (normals, high familial
risk, subthreshold disorders, first and recurrent episodes). Depressive and anxiety disorders are studied in
concert using both dimensional and categorical measurements. Central outcomes and determinants are
measured in detail at baseline and after one, two, four
and eight years of follow-up in a cohort of 2981
adults.
NESDA has three related main study objectives:
(1) Describing the long-term prognosis of depressive
and anxiety disorders in terms of course (chronicity, recurrence, development of comorbidity, suicidal behaviour) and public health consequences
(disability, mortality, costs).
(2) Examining clinical, psychosocial, biological and
genetic determinants of the long-term course and
consequences of depressive and anxiety disorders.
(3) Examining patient’s expectations, evaluation and
provision of (mental) health care and their association with the long-term course and consequences
of depressive and anxiety disorders.
It is important to emphasize that NESDA should be
regarded as an overarching research infrastructure
intended to foster specific research projects to address
focused research questions and hypotheses. Examples
of these research projects are, for instance, the examination of disability patterns among patients with different types of anxiety disorders (part of objective 1),
the exploration of a gene-environment interaction in
predicting the chronicity of depression (part of objective 2), and the examination of received mental health
care on the course of depressive and anxiety disorders
(part of objective 3). In addition to these specific
research projects, it is possible to frame some general
research hypotheses although these can only be based
on limited (indirect) scientific evidence (e.g. Keller
et al., 1992; Keller, 2006; Bruce et al., 2005). Three
main examples are: (1) the long-term course of anxiety
disorders is more chronic than that of depressive disorders, (2) the long-term course of anxiety disorders is
more homogeneous and therefore influenced by a lower
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
Netherlands Study of Depression and Anxiety (NESDA)
number of (diverse) determinants than the course of
depressive disorders, and (3) comorbidity of anxiety and
depressive disorders negatively influences the long-term
course and consequences of psychopathology.
In order to judge the interpretation and generalizability of NESDA findings, it is good to place the Dutch
mental health care situation in an international perspective. First, large-scale epidemiological studies have
shown that the prevalence of both depression and
anxiety disorders in the Netherlands is well in the
range of that in other high income countries such as
the US, Germany or Canada (Andrade et al., 2003). In
addition, the structure of the Dutch Health Care
System is comparable to that of several other European
countries (e.g. UK, Germany, Italy, Spain) in which the
general practitioner serves as the gatekeeper and referrals are needed for access to specialized mental health
care. Results from both the World Health Organization
(WHO) World Mental Health Surveys and the
European Study of the Epidemiology of Mental Disorders confirm that the proportion of diagnosed persons
receiving mental health treatment as well as the quality
of care received is well comparable to that in other high
income countries such as the US, UK, Germany, Spain
and Belgium (Wang et al., 2007; Alonso et al., 2004).
Consequently, we have no reason to believe that our
study results on the long-term course of (treated)
anxiety or depressive disorders are specific to the Dutch
situation only
NESDA consortium
The NESDA study is largely funded through a special
grant to stimulate psychiatric research (“Geestkracht”)
of the Netherlands Scientific Organization as well as
through matching funds from participating universities
and mental health organizations. A research consortium was established consisting of academic and nonacademic research groups, including the departments
of psychiatry, general practice and clinical psychology
of the VU University Medical Centre, the Leiden University Medical Centre and the University Medical
Centre Groningen, the Centre for Quality of Care
Research of Radboud University, the Netherlands
Institute for Health Services Research, and the Netherlands Institute of Mental Health and Addiction. This
collaboration guarantees access to the diverse expertise
of a large group of researchers. External (international)
researchers may collaborate and request access to the
data.
Copyright © 2008 John Wiley & Sons, Ltd
125
Methods
Sampling
NESDA has been designed to be representative of those
with depressive and anxiety disorders in different health
care settings and stages of the developmental history.
Therefore, the sample is stratified for setting (community, primary care and specialized mental health) and
set up to include a range of psychopathology: those
with no symptoms or disorders (‘controls’), those with
earlier episodes or at risk because of subthreshold symptoms or family history, and those with a current first or
recurrent depressive or anxiety disorder. The Composite Interview Diagnostic Instrument (CIDI) – lifetime
version 2.1 – was used to diagnose depressive and
anxiety disorders according to Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition
(DSM-IV) algorithms. The focus is on Dysthymia
(Dyst), Major Depressive Disorder (MDD), General
Anxiety Disorder (GAD), Panic Disorder (PAN), Social
Phobia (SocPhob) and Agoraphobia (AgoraPhob).
Table 1 shows the number of participants recruited
by setting and developmental stage of illness. Overall,
807 persons were recruited through mental health care
organizations, 564 persons through the community
setting and the remaining 1610 through primary care
(see later). Across recruitment setting, uniform inclusion and exclusion criteria were used. A general inclusion criterion was an age of 18 through 65 years. In
order to maintain representativity, only two exclusion
criteria existed: (1) a primary clinical diagnosis of a
psychiatric disorder not subject of NESDA which will
largely affect course trajectory: psychotic disorder,
obsessive compulsive disorder, bipolar disorder, or severe
addiction disorder, and (2) not being fluent in Dutch
since language problems would harm the validity and
reliability of collected data.
Recruitment from community samples
The NESDA community sample builds on two cohorts
that were already available through prior studies.
The first cohort is from the Netherlands Mental
Health Survey and Incidence Study (NEMESIS), a
community-based study described in detail elsewhere
(Bijl et al., 1998). NEMESIS applied a multistage, stratified sampling procedure using a random sample of
private households in 90 Dutch municipalities. The
adult household member with the most recent birthday
was asked to participate. A total of 7076 respondents
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
126
Penninx et al.
Table 1. Overview of the number of NESDA respondents per recruitment setting
Recruited from community
Subjects with life-time dep/anx disorder3
Subjects with parents with dep/anx
disorder4
Recruited from primary care
Controls: no dep/anx symptoms or
disorder
Subjects with subthreshold symptoms5
Subjects with non-current dep/anx
disorder1
Subjects with current dep/anx disorder1
Recruited from mental health organizations
Subjects with current dep/anx disorder1
Total
Total
(N)
N without any
dep/anx disorder
N with current1
dep/anx disorder
N with lifetime2
dep/anx disorder
303
261
0
138
104
47
303
123
373
373
0
0
141
353
141
0
0
0
0
353
743
0
743
743
807
0
807
807
2981
652
1701
2329
Note: Dep/anx disorder = depressive or anxiety disorder.
1
Current = six-month prevalence.
2
Lifetime disorders include current diagnoses as well as diagnoses earlier in life.
3
From NEMESIS (see Methods section).
4
From the ARIADNE study (see Methods section).
5
Defined as K-10 score ≥ 20 or positive anxiety screening questions or a DSM-diagnosis of minor depression, but not having
a (prior) history of dep/anx disorder according to the CIDI interview.
(69.7% of those eligible) participated and were interviewed with the CIDI, version 1.1 in 1996. Follow-up
interviews were conducted in 1997 (n = 5618) and 1999
(n = 4796). For NESDA, we included participants with
a 12-month prevalent depressive (MDD or Dysth) or
anxiety disorder diagnosis (GAD, SocPhob, AgoraPhob, PAN) at baseline or a diagnosis during any of the
two follow-up NEMESIS assessments who did not have
a CIDI diagnosis of any of the psychiatric diagnoses
belonging to the exclusion criteria (e.g. psychosis,
bipolar disorder, obsessive-compulsive disorder). Consequently, a total of 766 NEMESIS participants were
selected, of whom nine persons had died, eight persons
had left the Netherlands, and 87 could not be traced
despite several attempts. Of the 662 persons approached,
359 (54.2%) refused to participate, none were excluded
because of language problems, and 303 (45.8%) participated in NESDA. Those participating did not differ in
terms of age (p = 0.77), gender (p = 0.79), or type of
baseline disorder (anxiety, depression or comorbid
disorder, p = 0.97) from those not participating. An
Copyright © 2008 John Wiley & Sons, Ltd
important advantage of following this NEMESIS cohort
within NESDA, is that we have detailed information
on the prior 10-year history (since 1996) through
repeated (CIDI) assessments. Of the participating
303 persons, 104 had a current (six-month) prevalent
depressive or anxiety disorder at the NESDA baseline
assessment (see Table 1).
The second cohort exists of participants of the Adolescents at Risk for Anxiety and Depression (ARIADNE)
study (Landman-Peeters et al., 2005), a prospective
cohort study among 528 biological children (aged 13–
25 years) of parents who were treated for depressive or
anxiety disorder as outpatient at a mental health organization. These children can be considered at high risk
to develop depressive or anxiety disorders themselves.
The baseline ARIADNE interview in 2000 consisted
of a CIDI interview as well as self-report questionnaires.
Additional follow-up assessments were collected after
one year (n = 487), two years (n = 458) and four years
(n = 413). After official closure of the ARIADNE study
in 2004, 394 participants who were all fluent in Dutch
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
Netherlands Study of Depression and Anxiety (NESDA)
and who did not have a CIDI diagnosis of excluding
psychiatric diagnoses agreed to be contacted for additional research, of whom one died before contact, 10
could not be traced, 122 refused, and 261 participated
in NESDA. The 261 participants were more likely to
be female (64.0% versus 50.2%, p = 0.001) and have a
life-time depressive or anxiety disorder (31.0% versus
22.5%, p = 0.02) compared to the 267 no-participants,
but no age differences were present (p = 0.43). An
advantage of including this unique cohort is that
detailed, prospectively collected data is already available for the four years prior to NESDA.
Recruitment from primary care practices
Primary care patients were recruited from 65 general
practitioners (GPs) in the vicinity of the field sites
(Amsterdam, Groningen, Leiden). In selecting these
GPs, attention was paid to the use of an appropriate
electronic patient record databases which allows
uniform data extraction for research purposes. This is
important since collection of GP health care use information is part of NESDA, especially to address study
objective 3.
In the Netherlands, all patients are enlisted at a
general practice. For the selection of respondents, a
three-stage screening procedure was used. Screening
questionnaires were sent to a random sample of 23,750
patients aged 18–65 years who consulted their GP in
the last four months irrespective of reason for consultation. The screening questionnaire consisted of the
Kessler-10 (K-10; Kessler et al., 2003) with proven
screening qualities for affective disorders (Furukawa
et al., 2003; Kessler et al., 2003). Since the K-10 does
not contain questions for specific anxiety disorders, five
additional questions were added asking for the presence
(yes/no) of a panic attack, social phobia, agoraphobia,
general anxiety or nervousness, and psychotropic medication use during the last month. A screen-positive
score on the K-10 was defined as a validated K-10 score
of ≥20, (Furukawa et al., 2003) or a positive score on
any of the added anxiety questions. A total of 10,706
persons (45%) returned the screener. Those returning
the screener were more likely to be female (59.3% versus
50.0%, p < 0.001) and older (44.4 years versus 39.0 years,
p < 0.001) compared to those not returning the screener.
Of the screeners returned, 4887 were screen-positive
(46%) and these persons were approached for a short
phone-screen interview consisting of the CIDIshort form sections (MDD, Dysth, GAD, SocPhob,
Copyright © 2008 John Wiley & Sons, Ltd
127
Agoraphob, PAN). Those who fulfilled the CIDI-short
form criteria for a current depressive or anxiety disorder
during the phone-screen, and who were not treated for
psychiatric conditions in a psychiatric mental health
care setting, were invited to participate in the NESDA
study. In addition, a random selection of the screennegatives (both from the written screener or the phonescreen) were also invited to participate.
Figure 1 depicts the yield of the three-stage primary
care screening procedure.A total of 743 participants
with a current (six-month recency) and 353 participants
with a non-current depressive or anxiety disorder were
recruited, as well as 141 persons with subthreshold
symptoms (screen-positives not fulfilling diagnostic criteria or a CIDI DSM-IV minor depression diagnosis).
Finally, 373 participants with a screen-negative score
and no depressive or anxiety disorder participated and
constitute a “healthy control group”.
Recruitment from mental health organizations
The specialized mental health patients were recruited
from outpatient clinics of regional facilities for mental
health care around the three research sites. For each
newly enrolled patient at these outpatient clinics, a
mental health professional conducted a standardized
intake, which in most, but not all, facilities consisted
of a structured psychiatric interview [e.g. Mini International Neuropsychiatric Interview (MINI), Structured
Clinical Interview for DSM-IV (SCID)]. Patients who
received a primary diagnosis of depressive or anxiety
disorder, received brief information about NESDA. The
clinic staff of participating mental health care organizations submitted 1597 patients with primary depressive
or anxiety disorder for inclusion. Of these, 87 appeared
not to fulfil NESDA inclusion criteria when doublechecked by research staff, 58 could not be reached
despite multiple efforts, and 39 were excluded due to
language problems during phone contact. Of the other
1413 persons contacted by phone, 606 (43%) refused
participation and 807 (57%) participated in NESDA.
Those participating were slightly older (38.0 years
versus 36.5 years, p = 0.04) compared to the 635 who
refused, but there was no gender difference (p = 0.17).
Characteristics of study sample
The overall sample has a mean age of 41.9 years [standard deviation (SD) = 13.0] and consists of 1002 men
(33.6%) and 1979 women (66.4%). The respondents
have an average of 12.1 years of education (SD = 3.3)
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
128
Penninx et al.
Figure 1. Recruitment flow of NESDA respondents in the primary care setting. *Current = presence during the
last six months; non-current = presence before the last six months; subthreshold symptoms are defined as screenpositives or having minor depression according to the CIDI interview.
and 97% has the Dutch nationality. As shown in
Table 1, 1701 persons (57.1%) had a current (six-month)
depressive and/or anxiety disorder, whereas 2329
persons (78.1%) had a lifetime history. Table 2 illustrates that within the sample a total number of 3406
current and 5446 lifetime depressive and anxiety disorders are present. Especially the current numbers of
MDD (n = 1115), PAN (n = 670) and SocPhob (n = 665)
are high. As shown in Table 2, the majority of all cases
had an age of onset before age 30. Using the Life Chart
method, more than half of the persons with an anxiety
disorder and one-third of those with a MDD diagnosis
reported symptoms during at least 24 out of the 48
Copyright © 2008 John Wiley & Sons, Ltd
months prior to baseline. At baseline, a total of 748
(25.1% of the total sample) respondents were using antidepressants. Of these 748 respondents, 518 were using
a selective serotonin reuptake inhibitor (SSRI), 80 were
using a tricyclic antidepressant (TCA), and 172 were
using another antidepressant. In addition, 230 respondents were frequently (≥four days a week) using a
benzodiazepine.
Original sample size calculations were based on the
examination of course predictors within the smallest
subgroups of depressive and anxiety disorders. Beforehand, we calculated that a minimum of 160 persons per
subgroup were needed to detect a small difference (RR
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
Netherlands Study of Depression and Anxiety (NESDA)
129
Table 2. Baseline number of depressive or anxiety disorders among the 2981 NESDA respondents
Number of
Current1
disorders
Number of
Lifetime2
disorders
Percentage
disorders with
age of onset
<30 years
Percentage
disorders1
with duration
>2 years3
Major Depressive Disorder (MDD)
Dysthymia3
Panic disorder with/without agoraphobia
Social Phobia
Generalized Anxiety Disorder (GAD)
Agoraphobia without panic disorder
1115
305
670
665
464
187
1925
663
878
908
784
288
56.7
55.8
65.4
82.0
53.7
58.0
34.1
70.3
53.7
51.7
58.1
58.1
Total number of disorders
3406
5446
1
Current = six-month prevalence.
Lifetime disorders include current as well as diagnoses earlier in life.
3
Measured using the Life Chart method and defined as reporting symptoms during at least 24 out of the 48 months prior to
baseline.
2
= 1.5) in a dichotomous outcome (e.g. yes/no poor
course with a minimum outcome rate being 25%) given
a two-sided test, a model including 10 covariates, a
power of 80% and alpha of 0.05. Table 2 shows that our
smallest subgroup is 288 (for agoraphobia without panic
disorder). For many research questions, however, power
will be larger since analyses will be based on the larger
disorder groups and on continuous measures.
Measurements
Similar information is collected and similar procedures
were used for all participants, regardless of recruitment
setting. The baseline assessment lasted on average four
hours. Baseline assessments took place at one of the
seven clinic sites in the three regions around Amsterdam, Leiden and Groningen. If participants did not
want to come to the clinic site, they were offered transportation by taxi. A few persons (n = 60) who live far
away from the field site were offered in-home assessment, for which a van was equipped with all assessment
tools necessary to conduct the assessment as were it a
clinic site.
(Mental) health outcomes
Assessment of psychopathology
The NESDA baseline assessment includes various
indicators of presence, symptomatology, and history of
depressive and anxiety disorders (see Table 3). The
Copyright © 2008 John Wiley & Sons, Ltd
diagnoses of depression [minor depression (MinD),
MDD, Dyst] and anxiety disorders (GAD, SocPhob,
AgoraPhob, PAN) were established with the CIDI
(WHO version 2.1) which classifies diagnoses according to the DSM-IV criteria (American Psychiatric
Association, 2001). The CIDI is used worldwide and
WHO field research has found high interrater reliability (Wittchen et al., 1991), high test–retest reliability,
(Wacker et al., 2006) and high validity for depressive
and anxiety disorders (Wittchen et al., 1989;
Wittchen, 1994). Specially trained clinical research
staff conducted the CIDI. DSM-IV organic exclusion
rules were used in making diagnoses, and hierarchyfree diagnoses were made to allow for research into
comorbidity. At baseline, the life-time CIDI version
was used with added questions to determine the
research DSM-IV diagnosis of current minor depression (MinD). The life-time CIDI allows for the determination of the history, recency, duration and age of
onset of episodes. As has been feasibly used in other
large-scale studies [Epidemiologic Catchment Area
(ECA); Eaton et al. 1997] and NEMESIS (Spijker
et al., 2004), more detailed fluctuation of depressive
and anxiety symptoms during the past four years was
assessed with the Life Chart method. This instrument
first determines life events in this period to re-fresh
memory, and then assesses presence and severity of
symptoms during each quarter of the past four years
(Lyketsos et al., 1994).
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
130
Topic
Psychopathology
Presence of depressive disorder
Presence of anxiety disorder
Presence of alcohol disorder
Baseline measurement instrument
Reference
Method
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
CIDI: MDD, MinD, Dysth
CIDI: SocPhob, AgoraPhob, GAD, PAN
CIDI: alcohol abuse and dependency
Wittchen, 1994
Wittchen, 1994
Wittchen, 1994
Int
Int
Int
Inventory of depressive symptoms
Mood Disorder Questionnaire
Beck Scale for suicide ideation
Rush et al., 1996
Hirschfeld et al., 2000
Beck et al., 1979
SR
SR
Int
Beck Anxiety Index
Fear questionnaire
Beck et al., 1988
Marks and Mathews, 1979
SR
SR
Audit
Babor et al., 1989
SR
Dimensional categorization
General distress
Somatization symptoms
Mood and anxiety symptoms question.
Four-dimensional symptom questionnaire
Four-dimensional symptom questionnaire
Watson et al., 1995
Terluin et al., 2006
Terluin et al., 2006
SR
SR
SR
Course of symptoms
Life-chart
Lyketsos et al., 1994
Int
WHO-Disability Assessment Schedule II
Disability days
TIC-P
TIC-P and registration by GPs
Drug container observation + GP data
Presence + symptoms of disease
Information from proxies, GPs and the Netherlands Central Bureau of
Statistics
Chwastiak and Von Korff, 2003
Sheehan et al., 2001
Hakkaart-van Roijen, 2002
Hakkaart-van Roijen, 2002
n/a
n/a
n/a
SR
Int
Int
Int/GP
Int/GP
SR/GP
Proxy, GP/DR
Severity of depression
–depressive symptoms
–bipolar symptoms
–suicidal ideation
Severity of anxiety
–GAD/panic symptoms
–phobia symptoms
Severity of alcohol disorder
–alcohol dis. Symptoms
(Public) health consequences
Disability severity
Disability days
Work productivity
Health care use
Medication use
Somatic diseases
Mortality/causes of death
Note: SR = self-report; Int = interview; GP = data collection through general practitioner records; DR = death records.
Penninx et al.
Copyright © 2008 John Wiley & Sons, Ltd
Table 3. Collected baseline information on central (mental) health outcomes in NESDA
Netherlands Study of Depression and Anxiety (NESDA)
Severity of depressive symptoms was measured with
the 30-item Inventory of Depressive Symptomatology
self-report version, which has shown high correlations
with observer-rated scales and with established responsiveness to change (Rush et al., 1996). Although persons
with depression in the course of a bipolar disorder were
not included in the study, it was expected that some
respondents would report manic symptoms, which was
assessed using the Mood Disorder Questionnaire
(Hirschfeld et al., 2000). Current suicidality was assessed
with an interviewer-rated five-item scale of current
suicide ideation (Beck et al., 1979). Severity of generalized anxiety and panic symptoms was measured using
the 21-item Beck Anxiety Inventory (Beck et al., 1988),
whereas social and agoraphobia symptoms were measured using the 15-item Fear Questionnaire (Marks and
Mathews, 1979).
Given the debate about the validity of categorical
distinction between anxiety and depression (Goldberg,
1996) and the undisputed close relationship between
both, a dimensional approach to diagnosis was also
considered. A shortened Mood and Anxiety Symptom
Questionnaire was included, which uses Watson and
Clarcks tripartite model as the basis (Watson et al.,
1995). This 30-item scale has three subscales consisting
of lack of positive affect, negative affect and somatic
anxiety symptoms. Somatization and general distress
were determined with the validated four-dimensional
symptoms questionnaire (Terluin et al., 2006). Finally,
since the prevalence of alcohol use disorders was
expected to be high, the life-time CIDI-sections for
alcohol abuse and dependency were administered as
well as the Audit questionnaire to assess high-risk
drinking behaviour (Babor et al., 1989).
Assessment of public health consequences
From a patient and public health perspective, the prognosis of mental symptoms should be supplemented with
information on well-being, functioning, somatic health
and societal costs. Consequently, validated instruments
to assess disability (WHO-Disability Assessment
Schedule II (Chwastiak and von Korff, 2003), and
disability days (Sheehan et al., 2001), loss of productivity at work, and health care utilization (TIC-P;
Hakkaart-van Roijen, 2002) were included (see Table
3). An inventory of somatic disease was made by
detailed questions of presence of and receiving treatment for 20 chronic illnesses.
Copyright © 2008 John Wiley & Sons, Ltd
131
Determinants of (mental) health outcomes
Assessment of demographic and
personal characteristics
Detailed sociodemographic data were collected, including age, sex, ethnicity, place of living, and household
composition. Socio-economic information was collected by asking for education, occupation and income
of the respondents and their partner and parents. Personal history questions included a structured inventory
of trauma exposure during childhood (emotional
neglect, psychological abuse, physical abuse, sexual
abuse and important life-events in early life). The
Brugha questionnaire (Brugha et al., 1985) assessed
exposure to 12 important negative events during life
such as death or serious illness of other family members,
unemployment and violence experience. Finally, the
Daily Hassles Questionnaire measures day-to-day experience of stressful circumstances such as work, private
or financial problems or arguments (Kanner et al.,
1981).
Psychosocial function
Details about social support from the four most intimate persons is assessed through the social support
inventory (Stansfeld and Marmot, 1992) and self-report
questionnaires of loneliness and affiliation are used (de
Jong-Gierveld and Kamphuis, 1985). The Karasek questionnaire examines work content and environment
(Karasek et al., 1998). Personality is operationalized
using the NEO personality questionnaire, a 60-item
questionnaire measuring five personality domains: neuroticism, extraversion, agreeableness, conscientiousness, and openness to experience (Costa and McCrae,
1995). Locus of control is assessed by a five-item mastery
scale (Pearlin and Schooler, 1978).
Cognitions have been hypothesized to be important
as predisposing factors for (a poor course of) depression
and anxiety disorders. The Leiden index of depression
sensitivity assesses the extent in which dysfunctional
cognitions (e.g. rumination, hopelessness, aggression)
are triggered during normal mood variations (van der
Does, 2002). The anxiety sensitivity index explores fear
of anxiety-related somatic sensations (Peterson and
Reiss, 1992) and the Penn–State Worry Index assesses
the extent to which persons worry frequently and
extensively (Meyer et al., 1990). Some relevant (implicit)
personality constructs are not measurable through
questionnaires because they operate in an automatic
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
132
Penninx et al.
(unconscious) mode that is not accessible to introspection. Therefore, implicit trait anxiety and depression
were assessed by means of a modified Implicit Association Test (Greenwald et al., 1998) that was designed to
measure implicit associations between self items on the
one hand and anxiety-related and depression-related
items on the other.
Attitude towards health care
The patients’ perspective is essential in any effort to
reduce long-term effects of disorders. Very little is
known about the long-term development in relevant
attitudes, expectations and motivation of patients with
depressive and anxiety disorders. This is surprising, as
depression and anxiety are disorders with high levels of
non-adaptive illness behaviour. NESDA included the
Quote instrument (Sixma et al., 1998) to measure experience and evaluation of care for mental health and the
Perceived Need of Care questionnaire (Meadows et al.,
2000) to assess a person’s care needs.
(Physiological) health indicators
Depressive and anxiety disorders are strongly associated
to somatic health. To account for these associations
and to further examine potential underlying biological
and behavioural mechanisms, NESDA included (physiological) health and health behaviour indicators (Table
4). The International Physical Activity Questionnaire
(IPAQ) calculates energy expenditure based on sports
and other daily activities during a regular day (Craig
et al., 2003) In addition, sleep behaviour (using the
Insomnia Rating Scale; Levine et al., 2003), smoking
behaviour and nicotine dependence (Fagerstrom questionnaire; Heatherton et al., 1991) and regular drug and
alcohol use were measured. An inventory of 20 somatic
conditions was included, and medications used in the
prior month were registered (by observation of the containers brought in). Participants who used benzodiazepines in the prior month were questioned about
dependency using the Bendep SRQ (Oude Voshaar et
al., 2003). Since self-reported disease status may be
biased by mood, we also included objective, generic
indicators of health status: a peak flow assessment to
measure lung function capacity and a handgrip strength
assessment using a hand-held dynanometer. Body composition assessment included objective, standardized
assessments of height, weight and hip and abdominal
circumference.
Copyright © 2008 John Wiley & Sons, Ltd
Systolic and diastolic blood pressure were measured
twice in a supine position using an electronic omron
phygmomanometer. Doppler assessment of ankle and
arm blood pressure allowed calculation of the ankle/
brachial index, an indicator of peripheral atherosclerosis (Newman et al., 1993). Since all baseline assessments took place in the morning, respondents came in
after an overnight fast. This allowed the draw of a
fasting sample of 50 millilitres of blood, which were
immediately transferred to a local laboratory to start
processing within one hour. Routine assays included
assessment of hemoglobin, hematocrit, creatinine,
total, HDL and LDL cholesterol, glucose, triglycerides,
ASAT, ALAT, gamma-GT, thyroid stimulated hormone
(TSH) and Free T4. Most of the blood sample, however,
was processed and stored at −85 °C for later assaying.
Physiological assessment of stress systems
Two important stress systems have been hypothesized
to be of importance in the adverse health effects of
depressive and anxiety disorders: the HPA axis and the
autonomic nervous system. These stress systems may be
dysregulated and may determine the long-term course
of depressive or anxiety disorders. Activity of the HPAaxis was assessed by free cortisol assessment using seven
saliva samples per respondent. As a measure of a natural
‘stress’ response of the HPA-axis, the morning cortisol
awakening response was assessed by taking saliva
samples at awakening time, 30, 45 and 60 minutes later
(Wust et al., 2000). To obtain information on basal
levels and the circadian rhythm, additional saliva
samples were collected at 22 p.m. and 23 p.m. Afterwards, participants were instructed to ingest 0.5 milligrammes of dexamethasone, a specific antagonist of the
glucocorticoid receptor which inhibits adrenocorticotropic hormone (ACTH) release at the pituitary gland.
Immediately after awakening the next morning, the
extent of cortisol inhibition was determined by a
seventh saliva sample (Gaab et al., 2002) Respondents
collected saliva samples on regular (work) days using
cotton swaps which were returned by mail. After
receipt, saliva was spun down, stored at −85 °C and
assayed.
Physiological signals of the autonomic nervous
system were measured using the ambulatory monitoring
system (VU-AMS), of which reliability and recording
methodology have been described previously (de Geus
et al., 1995). Respondents wore the VU-AMS assessment unobtrusively underneath clothing for two hours
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
Netherlands Study of Depression and Anxiety (NESDA)
133
Table 4. Collected baseline information on important determinants of (mental) health outcomes in NESDA
Topic
Baseline measurement instrument
Demographic and personal characteristics
Demographics
Age, gender, ethnicity
Standard questions
Partner + household status
Standard questions
Socio-economic status
Education, income, occupation
Personal history
Important life events
Brugha questionnaire
Childhood trauma
NEMESIS questionnaire
Daily hassles
Daily Hassles questionnaire
Patient’s perspective
Psychosocial function
Social support and activity
Work content/environment
Loneliness
Affiliation
Personality
Locus of control
Worry
Anxiety cognitions
Depression cognitions
Experimental cognitive task
Health care attitude
Need of care
Patient evaluation of care
Close Person Inventory
Karasek questionnaire
De Jong-Gierveld loneliness scale
Van Tilburg scale
NEO-FFI questionnaire
Pearlin and Schooler mastery scale
Penn–State Worry Scale
Anxiety Sensitivity Index
LEIDS questionnaire
Implicit Association Test
Perceived Need of Care
questionnaire
QUOTE questionnaire
(Biological) health and genetic measures
Health behaviour
Regular alcohol intake
Drinking behavior questions
Drugs
Soft and hard drugs questions
Smoking
Past + current smoking questions
Nicotine dependence
Fagerstrom questionnaire
Benzodiazepine dependence
Bendep SRQ
Physical activity
IPAQ questionnaire
(Biological) health markers
Presence of 20 diseases
Standard self-report questions +
GP data
Pain
Chronic graded pain scale
Sleep
Insomnia Rating Scale
Pulmonary function
Peak flow measurement
Muscle strength
Grip strength assessment
Biomarkers
Fasting blood sample
Body composition
Weight, height, waist + hip
circumference
Blood pressure (BP)
Systolic and diastolic BP
assessment
Copyright © 2008 John Wiley & Sons, Ltd
Reference
Method
n/a
n/a
n/a
Int
Int
Int
Brugha et al., 1985
de Graaf et al., 2002
Kanner et al., 1981
Int
Int
SR
Stansfeld et al., 1992
Karasek et al., 1998
de Jong-Gierveld and
Kamphuis, 1985
van Tilburg, 1998
Costa and McCrae, 1995
Pearlin and Schooler, 1978
Meyer et al., 1990
Peterson and Reiss, 1992
van der Does et al., 2002
Greenwald et al., 1998
SR
Int
SR
SR
SR
SR
SR
SR
SR
CT
Meadows et al., 2000
Int
Sixma et al., 1998
SR
n/a
n/a
n/a
Heatherton et al., 1991
Oude Voshaar et al., 2003
Craig et al., 2003
SR
SR
SR
Int
Int
SR
n/a
Int, GP
von Korff, 1992
Levine et al., 2003
n/a
n/a
n/a
n/a
Int
SR
ME
ME
Blood
ME
n/a
ME
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
134
Penninx et al.
Table 4. continued
Topic
Peripheral atherosclerosis
Autonomic nervous system
HPA-axis (salivary cortisol)
Genetic measures
Family history
DNA/lymphocytes
Proteomics
Gene-expression (RNA)
Baseline measurement instrument
Reference
Method
Doppler assessment of ankle-arm
index
Electro + impedance cardiography
Seven saliva samples, including
DST test
n/a
ME
de Geus et al., 1995
n/a
ME
Saliva
Family tree inventory
Full blood
Serum
Before + after LPS-challenge
Fyer and Weissman, 1999
Boomsma et al., 2008
Boomsma et al., 2008
Boomsma et al., 2008
Int
Blood
Blood
Blood
Note: SR = self-report; Int = interview; GP = data collection through general practitioner records; Blood = data collection via
fasting blood sample; CT = computer task; ME = medical examination.
during which continuous time series of R wave-to-R
wave intervals and respiration rates were registered
from a three-lead electrocardiogram and a four-lead
impedance cardiogram. From these, valid indicators
(e.g. heart rate variability, pre-ejection period, respiration sinus arrhythmia) of parasympathetic and sympathetic cardiac activity were obtained.
Genetic determinants
Depressive and anxiety disorders are highly heritable,
with heritability estimates between 35–40% (Sullivan
et al., 2000). Consequently, it is likely that underlying
genetic factors (in interaction with environmental
factors) determine the onset and course of depressive
and anxiety disorders. NESDA is therefore set up to
provide genetic indicators for future genetic research.
Briefly, for all participants DNA was isolated from the
baseline blood sample. Through funding from the
fNIH GAIN programme (www.fnih.gov/gain), whole
genome scan analysis were conducted for 1860 NESDA
participants to be compared with 1860 controls from
the Netherlands Twin Registry (see for more details:
Boomsma et al., 2008). For all respondents, lymphocytes
were stored so that future genomic information
can be obtained. In addition, to examine the genome
responsiveness at the individual genetic background of
individuals, we also set up samples for later geneexpression profiling and proteomics. For this purpose,
we stored one heparin tube with blood at −80 °C, and
stored another heparin tube after a lipopolysacharride
Copyright © 2008 John Wiley & Sons, Ltd
(LPS) challenge had been added and incubated for five
hours. After future micro array analyses, geneexpression profiling in unchallenged and challenged
samples can for instance be compared between
depressed or anxious patients and controls. Finally,
family history of depressive and anxiety disorders is
explored using the family tree method (Fyer and
Weissman, 1999).
Additional data collection
Functional magnetic resonance imaging (fMRI)
Although several functional magnetic resonance
imaging (fMRI) studies have now confirmed neurobiological abnormalities among depression and anxiety
patients (Anand and Shekhar, 2003; Deckersbach
et al., 2006), the specificity of these abnormalities, and
associations with e.g. severity and duration have not
been fully explored. Also the prognostic importance of
(change in) neurobiological parameters for the course
of depression and anxiety disorders remains largely
unknown, which is the main reason for including fMRI
assessments in a subgroup of the NESDA cohort. Both
volumetric and functional MRI using a 3 Tesla MRI
scanner was performed in five subgroups (total n = 301):
controls (n = 69), and current (one-month recency)
cases with MDD (n = 94), social phobia (n = 28), panic
disorder (n = 26) and in cases with multiple disorders
(n = 88). Included paradigms are the Eckman Faces task
(Canli et al., 2005), the Tower of London planning task
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
Netherlands Study of Depression and Anxiety (NESDA)
(van den Heuvel et al., 2003) and an episodic memory
task of encoding and retrieval (Daselaar et al., 2003).
fMRI assessments will be repeated two and four years
after baseline.
Information from GPs
For respondents recruited in primary care, additional
data from GPs were collected. Participating GPs filled
out a questionnaire about practice characteristics and
their medical experience and attitude towards (mental)
health care. In addition, the GP’s electronic patient
register data were extracted during the NESDA followup period. This data extraction includes information
on medical history, number of and reasons for GP visits,
prescribed medication, and referrals starting from the
year prior to baseline. This will be used for e.g. data
verification of health care utilization and health care
costs. Since the charging to the insurance company is
connected with completion of the electronic patient
record, this information is rather complete. The consequent coding of somatic, social and psychiatric diagnoses in electronic patient records provides reliable
information on daily care (Okkes et al., 2002).
Procedures
In the baseline assessment, the use of a laptop computer
was central. Interviews were administered with computer-assisted personalized interviewing procedures with
data entry checks on outliers and routing. All interviews were taped to monitor data-quality and interviewer performance. When the assessment was
completed, respondents were compensated with a small
incentive (gift certificate of 15 euro and payment of
travel costs) for their time and cooperation.
Staff training and supervision
In order to conduct the study, more than 40 research
assistants have been trained. The majority of research
assistants consisted of psychologists, nurses or residents
in psychiatry. Research assistants received one week of
training by the fieldwork coordinator. A research assistant was certified to conduct assessments after approval
of audiotapes of at least two complete interviews. Question wording and probing behaviour of interviewers was
constantly monitored by checking a random selection
of about 10% of all taped interviews. In addition, a
continuous monitoring system of interviewer variances
and interviewer specific item-non response was maintained through computer analyses in SPSS.
Copyright © 2008 John Wiley & Sons, Ltd
135
Data management and control
The NESDA coordinating centre at the Department of
Psychiatry of the VU University Medical Centre serves
as data monitoring centre. The data management team
focuses on data archiving, checking of data errors, creation of (summary) variables and scales, and maintaining and updating central data bases. Electronic data
from the interviews were sent on a weekly basis to the
coordinating centre, where data were entered in central
databases. Data quality checks were routinely carried
out to review missing data and check for
inconsistencies.
Ethical issues
The study protocol was approved centrally by the
Ethical Review Board of the VU University Medical
Centre and subsequently by local review boards of each
participating centre. After full verbal and written
information about the study, written informed consent
was obtained from all participants at the start of baseline assessment. This written informed consent asked
for permission to use genetic information, to retrieve
health care information from physicians, and to link
respondent information to external data banks (e.g.
mortality or hospitalization databases). Confidentiality
of data is maintained by using a unique research ID
number for each respondent, which enables to identify
individuals without using names. Only a limited number
of persons (principal investigator, data manager) have
access to the record that link ID number to identifiable
information.
Time line and follow-up assessments
Recruitment of the NESDA sample started in September 2004 and was completed in February 2007. In
September 2005 and September 2006, the one-year and
two-year follow-up assessments started. The one-year
follow-up assessment consists of a written questionnaire
containing the most important self-report instruments
to determine demographic changes, recent life events
and the course and consequences of anxiety and depression symptoms. The two-year follow-up assessment consists of a face-to-face clinic visit, in which baseline
assessments – except those concerning stable concepts
– are repeated. A few additional assessments were
included: the CIDI bipolar disorder section, questions
about experienced side effects and effectiveness
of used psychotropic medication, a computerized
working memory task (N-back; Carlson et al., 1998),
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
136
Penninx et al.
a computerized exogeneous cueing task (Koster et al.,
2005) to assess attentional bias for depression and
anxiety, and an index of seasonality of symptoms
(Seasonal Pattern Assessment Questionnaire; Mersch
et al. 2004). The four-year and eight-year follow-up
assessments will start in September 2008 and 2012,
respectively.
Conclusion
NESDA is multisite, longitudinal, naturalistic cohort
study examining the eight-year course and consequences of depressive and anxiety disorders. Although psychiatric epidemiology has provided us insight into the
high prevalence of depressive and anxiety disorders and
their large impact on public health, there is relatively
much less known about the long-term course of these
disorders and its determinants. NESDA’s large sample
size and detailed assessment of both mental health outcomes and determinants. In sum, NESDA provides a
unique opportunity to learn more about the prognosis
of two of the most common and burdensome disorders
for society. Better prediction of prognosis will allow
more accurate and efficient planning of the limited
health care resources and thereby ultimately contribute
to health improvement of patients with depressive and
anxiety disorders.
Acknowledgement
The infrastructure for the NESDA study is funded through
the Geestkracht programme of the Dutch Scientific Organization (ZON-MW, grant number 10-000-1002) and matching
funds from participating universities and mental health care
organizations (VU University Medical Centre, GGZ
Buitenamstel, GGZ Geestgronden, Leiden University
Medical Centre, GGZ Rivierduinen, University Medical
Centre Groningen, Lentis, GGZ Friesland, GGZ Drenthe).
Declaration of Interests
Dr. Nolen has received speaking fees from Astra Zeneca,
Eli Lilly, Pfizer, Servier, Wyeth; unrestricted research
funding from Astra Zeneca, Eli Lilly, GlaxoSmithKline, Wyeth; and served on advisory boards for Astra
Zeneca, Cyberonics, Eli Lilly, GlaxoSmithKline, Pfizer,
Servier. None of the other authors have any financial
disclosures.
References
Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha
TS, Bryson H, de Girolamo G, de Graaf R, Demyttenaere
K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V,
Copyright © 2008 John Wiley & Sons, Ltd
Lepine JP, Ormel J, Polidori G, Russo LJ, Vilagut G,
Almansa J, Arbabzadeh-bouchez S, Autonell J, Bernal M,
Buist-Bouwman MA, Codony M, Domingo-Salvany A,
Ferrer M, Joo SS, Martinez-Alonso M, Matschinger H,
Mazzi F, Morgan Z, Morosini P, Palacin C, Romera B,
Taub N, Vollebergh WAM (2004). Use of mental health
services in Europe: results from the European Study of the
Epidemiology of Mental Disorders (ESEMeD) project.
Acta Psychiatr Scand Suppl 420: 47–54.
American Psychiatric Association (2001). Diagnostic and
Statistical Manual of Mental Disorders, fourth edition.
Washington, DC: American Psychiatric Publishing.
Anand A, Shekhar A (2003). Brain imaging studies in mood
and anxiety disorders: special emphasis on the amygdala.
Ann NY Acad Sci 985: 370–88.
Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RB, de
Graaf R, Vollebergh W, Dragomirecka E, Kohn R, Keller
M, Kessler RC, Kawakami N, Kilic C, Offord D, Ustun
TB, Wittchen HU (2003). The epidemiology of major
depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int J
Methods Psychiatr Res 12: 3–21. DOI 10.1002/mpr.138
Andrews JS, Stephens DN (1990). Drug discrimination
models in anxiety and depression. Pharmacol Ther 47:
267–80.
Angst J (1996). Comorbidity of mood disorders: a longitudinal prospective study. Br J Psychiatry Suppl 31–7.
Babor TF, Kranzler HR, Lauerman RJ (1989). Early detection
of harmful alcohol consumption: comparison of clinical,
laboratory, and self-report screening procedures. Addict
Behav 14: 139–57.
Beck AT, Kovacs M, Weissman A (1979). Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult
Clin Psychol 47: 343–52.
Beck AT, Epstein N, Brown G, Steer RA (1988). An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56: 893–7.
Beekman AT, de Beurs E, van Balkom AJ, Deeg DJ, van DR,
van TW (2000). Anxiety and depression in later life: Cooccurrence and communality of risk factors. Am J
Psychiatry 157: 89–95.
Bijl RV, Ravelli A (2000). Psychiatric morbidity, service use,
and need for care in the general population: results of The
Netherlands Mental Health Survey and Incidence Study.
Am J Public Health 90: 602–7.
Bijl RV, van ZG, Ravelli A, de RC, Langendoen Y (1998).
The Netherlands Mental Health Survey and Incidence
Study (NEMESIS): objectives and design. Soc Psychiatry
Psychiatr Epidemiol 33: 581–86.
Boomsma DI, Willemsen G, Sullivan PF, Heutink P, Meijer
P, Sondervan D, Kluft C, Smit G, Nolen WA, Zitman FG,
Smit JH, Hoogendijk WJ, van Dyck R, de Geus EJ,
Penninx BW (2008). Genome-wide association of Major
Depression: Description of samples for the GAIN Major
Depressive Disorder Study: NTR and NESDA biobank
projects. Eur J Hum Genet 16: 335–42.
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
Netherlands Study of Depression and Anxiety (NESDA)
Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR
(1996). Treatment outcomes for primary care patients
with major depression and lifetime anxiety disorders. Am
J Psychiatry 153: 1293–300.
Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB,
Pagano M, Shea MT, Keller MB (2005). Influence of
psychiatric comorbidity on recovery and recurrence in
generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 162:
1179–87.
Brugha T, Bebbington P, Tennant C, Hurry J (1985). The list
of threatening experiences: a subset of 12 life event categories with considerable long-term contextual threat.
Psychol Med 15: 189–94.
Buist-Bouwman MA, de Graaf R, Vollebergh WA, Alonso J,
Bruffaerts R, Ormel J (2006). Functional disability of
mental disorders and comparison with physical disorders:
a study among the general population of six European
countries. Acta Psychiatr Scand 113: 492–500.
Canli T, Cooney RE, Goldin P, Shah M, Sivers H, Thomason
ME, Whitfield-Gabrieli S, Gabrieli JD, Gotlib IH (2005).
Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport 16: 1267–70.
Carlson S, Martinkauppi S, Rama P, Salli E, Korvenoja A,
Aronen HJ (1998). Distribution of cortical activation
during visuospatial n-back tasks as revealed by functional
magnetic resonance imaging. Cereb Cortex 8: 743–52.
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW,
Harrington H, McClay J, Mill J, Martin J, Braithwaite A,
Poulton R (2003). Influence of life stress on depression:
moderation by a polymorphism in the 5-HTT gene.
Science 301: 386–9.
Chwastiak LA, von Korff M (2003). Disability in depression
and back pain: evaluation of the World Health Organization Disability Assessment Schedule (WHO DAS II) in
a primary care setting. J Clin Epidemiol 56: 507–14.
Cooper-Patrick L, Crum RM, Ford DE (1994). Characteristics
of patients with major depression who received care in
general medical and specialty mental health settings. Med
Care 32: 15–24.
Costa PT, McCrae RR (1995). Domains and facets: hierarchical personality assessment using the revised NEO personality inventory. J Pers Assess 64: 21–50.
Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth
ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis
JF, Oja P (2003). International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports
Exerc 35: 1381–95.
Daselaar SM, Veltman DJ, Rombouts SA, Raaijmakers JG,
Jonker C (2003). Neuroanatomical correlates of episodic
encoding and retrieval in young and elderly subjects.
Brain 126: 43–56.
de Geus EJ, Willemsen GH, Klaver CH, van Doornen LJ
(1995). Ambulatory measurement of respiratory
sinus arrhythmia and respiration rate. Biol Psychol 41:
205–27.
Copyright © 2008 John Wiley & Sons, Ltd
137
Deckersbach T, Dougherty DD, Rauch SL (2006). Functional
imaging of mood and anxiety disorders. J Neuroimaging
16: 1–10.
de Graaf R, Bijl RV, Smit F, Vollebergh WA, Spijker J (2002).
Risk factors for 12-month comorbidity of mood, anxiety,
and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study. Am J
Psychiatry 159: 620–9.
de Jong Gierveld J, Kamphuis (1985). The development of a
rasch type loneliness scale. Appl Psychol Meas 9:
289–99.
Duncan-Jones P, Fergusson DM, Ormel J, Horwood LJ (1990).
A model of stability and change in minor psychiatric
symptoms: results from three longitudinal studies. Psychol
Med Monogr Suppl 18: 1–28.
Eaton WW, Anthony JC, Gallo J, Cai G, Tien A, Romanoski
A, Lyketsos C, Chen LS (1997). Natural history of Diagnostic Interview Schedule/DSM-IV major depression.
The Baltimore Epidemiologic Catchment Area follow-up.
Arch Gen Psychiatry 54: 993–9.
Furukawa TA, Kessler RC, Slade T, Andrews G (2003). The
performance of the K6 and K10 screening scales for
psychological distress in the Australian National Survey
of Mental Health and Well-Being. Psychol Med 33:
357–62.
Fyer AJ, Weissman MM (1999). Genetic linkage study of
panic: clinical methodology and description of pedigrees.
Am J Med Genet 88: 173–81.
Gaab J, Huster D, Peisen R, Engert V, Schad T, Schurmeyer
TH, Ehlert U (2002). Low-dose dexamethasone suppression test in chronic fatigue syndrome and health. Psychosom Med 64: 311–8.
Goldberg D (1996). A dimensional model for common mental
disorders. Br J Psychiatry Suppl 44–9.
Goldberg D, Huxley P (1992). Common mental disorders.
London: Routledge.
Greenwald AG, McGhee DE, Schwartz JL (1998). Measuring
individual differences in implicit cognition: the implicit
association test. J Pers Soc Psychol 74: 1464–80.
Hakkaart-van Roijen L (2002). Trimbos/iMTA questionnaire
for costs associated with psychiatric illness (TIC-P).
Rotterdam: Institute for Medical Technology Assessment.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO
(1991). The Fagerstrom Test for Nicotine Dependence: a
revision of the Fagerstrom Tolerance Questionnaire. Br J
Addict 86: 1119–27.
Hecht H, von ZD, Wittchen HU (1990). Anxiety and depression in a community sample: the influence of comorbidity
on social functioning. J Affect Disord 18: 137–44.
Heim C, Newport DJ, Wagner D, Wilcox MM, Miller AH,
Nemeroff CB (2002). The role of early adverse experience
and adulthood stress in the prediction of neuroendocrine
stress reactivity in women: a multiple regression analysis.
Depress Anxiety 15: 117–25. DOI:10.1002/da.10015
Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn
L, Keck PE, Jr, Lewis L, McElroy SL, Post RM, Rapport
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
138
Penninx et al.
DJ, Russell JM, Sachs GS, Zajecka J (2000). Development
and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J
Psychiatry 157: 1873–5.
Judd LL (1997). The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 54: 989–91.
Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell
W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice
JA, Keller MB (1998). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55:
694–700.
Kanner AD, Coyne JC, Schaefer C, Lazarus RS (1981). Comparison of two modes of stress measurement: daily hassles
and uplifts versus major life events. J Behav Med 4:
1–39.
Karasek R, Brisson C, Kawakami N, Houtman I, Bongers P,
Amick B (1998). The Job Content Questionnaire (JCQ):
an instrument for internationally comparative assessments of psychosocial job characteristics. J Occup Health
Psychol 3: 322–55.
Keller MB (2006). Social anxiety disorder clinical course and
outcome: review of Harvard/Brown Anxiety Research
Project (HARP) findings. J Clin Psychiatry Suppl 67(12):
14–9.
Keller MB, Hanks DL (1993). Course and outcome in panic
disorder. Prog Neuropsychopharmacol Biol Psychiatry 17:
551–70.
Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J,
Taylor J (1984). Long-term outcome of episodes of major
depression. Clinical and public health significance. JAMA
252: 788–92.
Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W,
Hirschfeld RM, Shea T (1992). Time to recovery, chronicity, and levels of psychopathology in major depression. A
5-year prospective follow-up of 431 subjects. Arch Gen
Psychiatry 49: 809–16.
Kendler KS, Heath AC, Martin NG, Eaves LJ (1987). Symptoms of anxiety and symptoms of depression. Same
genes, different environments? Arch Gen Psychiatry 44:
451–7.
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M,
Eshleman S, Wittchen HU, Kendler KS (1994). Lifetime
and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National
Comorbidity Survey. Arch Gen Psychiatry 51: 8–19.
Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC,
Hiripi E, Howes MJ. Normand SL, Manderscheid RW,
Walters EE, Zaslavsky AM (2003). Screening for serious
mental illness in the general population. Arch Gen Psychiatry 60: 184–9.
Koster EH, De Raedt R., Goeleven E, Franck E, Crombez G
(2005). Mood-congruent attentional bias in dysphoria:
maintained attention to and impaired disengagement
from negative information. Emotion 5: 446–55.
Copyright © 2008 John Wiley & Sons, Ltd
Krueger RF (1999). The structure of common mental disorders. Arch Gen Psychiatry 56: 921–6.
Landman-Peeters KM, Hartman CA, van der PG, den Boer
JA, Minderaa RB, Ormel J (2005). Gender differences in
the relation between social support, problems in parentoffspring communication, and depression and anxiety.
Soc Sci Med 60: 2549–59.
Levine DW, Kripke DF, Kaplan RM, Lewis MA, Naughton
MJ, Bowen DJ, Shumaker SA (2003). Reliability and
validity of the Women’s Health Initiative Insomnia
Rating Scale. Psychol Assess 15: 137–48.
Lyketsos CG, Nestadt G, Cwi J, Heithoff K, Eaton WW
(1994). The life-chart method to descibe the course
of psychopathology. Int J Methods Psychiatr Res 4:
143–55.
Marks IM, Mathews AM (1979). Brief standard self-rating for
phobic patients. Behav Res Ther 17: 263–7.
Meadows G, Harvey C, Fossey E, Burgess P (2000). Assessing
perceived need for mental health care in a community
survey: development of the Perceived Need for Care
Questionnaire (PNCQ). Soc Psychiatry Psychiatr Epidemiol 35: 427–35.
Merikangas KR, Angst J, Eaton W, Canino G, Rubio-Stipec
M, Wacker H, Wittchen HU, Andrade L, Essau C,
Whitaker A, Kraemer H, Robins LN, Kupfer DJ (1996).
Comorbidity and boundaries of affective disorders with
anxiety disorders and substance misuse: results of an
international task force. Br J Psychiatry Suppl 58–67.
Merikangas KR, Chakravarti A, Moldin SO, Araj H,
Blangero JC, Burmeister M, Crabbe J, Jr, Depaulo JR, Jr,
Foulks E, Freimer NB, Koretz DS, Lichtenstein W,
Mignot E, Reiss AL, Risch NJ, Takahashi JS (2002).
Future of genetics of mood disorders research. Biol Psychiatry 52: 457–77.
Mersch PP, Vastenburg NC, Meesters Y, Bouhuys AL,
Beersma DG, van den Hoofdakker RH, den Boer JA
(2004). The reliability and validity of the Seasonal Pattern
Assessment Questionnaire: a comparison between patient
groups. J Affect Disord 80: 209–19.
Meyer TJ, Miller ML, Metzger RL, Borkovec TD (1990).
Development and validation of the Penn State Worry
Questionnaire. Behav Res Ther 28: 487–95.
Murray CJ, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990–2020: Global Burden
of Disease Study. Lancet 349: 1498–1504.
Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP,
Borhani NO, Wolfson SK (1993). Ankle-arm index as a
marker of atherosclerosis in the Cardiovascular Health
Study. Cardiovascular Heart Study (CHS) Collaborative
Research Group. Circulation 88: 837–45.
Okkes IM, Becker HW, Bernstein RM, Lamberts H (2002).
The March 2002 update of the electronic version of
ICPC-2. A step forward to the use of ICD-10 as a nomenclature and a terminology for ICPC-2. Fam Pract 19:
543–6.
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
Netherlands Study of Depression and Anxiety (NESDA)
Ormel J, Von Korff M, Ustun TB, Pini S, Korten A,
Oldehinkel T (1994). Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health
Care. JAMA 272: 1741–8.
Oude Voshaar RC, Mol AJ, Gorgels WJ, Breteler MH, van
Balkom AJ, van de Lisdonk EH, Kan CC, Zitman FG
(2003). Cross-validation, predictive validity, and time
course of the Benzodiazepine Dependence Self-Report
Questionnaire in a benzodiazepine discontinuation trial.
Compr Psychiatry 44: 247–55.
Pearlin LI, Schooler C (1978). The structure of coping.
J Health Soc Behav 19: 2–21.
Peterson RA, Reiss S (1992). Anxiety Sensitivity Index.
Worthington, OH: International Daignostic Systems
Publishing Corporation.
Piccinelli M, Wilkinson G (1994). Outcome of depression in
psychiatric settings. Br J Psychiatry 164: 297–304.
Pollack MH, Otto MW (1997). Long-term course and outcome
of panic disorder. J Clin Psychiatry Suppl 58(2): 57–60.
Roy-Byrne PP, Stang P, Wittchen HU, Ustun B, Walters EE,
Kessler RC (2000). Lifetime panic-depression comorbidity
in the National Comorbidity Survey. Association with
symptoms, impairment, course and help-seeking. Br J
Psychiatry 176: 229–35.
Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH
(1996). The Inventory of Depressive Symptomatology
(IDS): psychometric properties. Psychol Med 26:
477–86.
Sartorius N, Ustun TB, Lecrubier Y, Wittchen HU (1996).
Depression comorbid with anxiety: results from the WHO
study on psychological disorders in primary health care.
Br J Psychiatry Suppl 38–43.
Sheehan TJ, DeChello LM, Garcia R, Fifield J, Rothfield N,
Reisine S (2001). Measuring disability: application of the
Rasch model to activities of daily living (ADL/IADL).
J Outcome Meas 5: 839–63.
Sixma HJ, Kerssens JJ, Campen CV, Peters L (1998). Quality
of care from the patients’ perspective: from theoretical
concept to a new measuring instrument. Health Expect
1: 82–95.
Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R,
Beekman A (2006). Costs of nine common mental disorders: implications for curative and preventive psychiatry.
J Ment Health Policy Econ 9: 193–200.
Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen
WA (2002). Duration of major depressive episodes in the
general population: results from the Netherlands Mental
Health Survey and Incidence Study (NEMESIS). Br J
Psychiatry 181: 208–13.
Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen
WA (2004). Determinants of persistence of major depressive episodes in the general population. Results from the
Netherlands Mental Health Survey and Incidence
Study (NEMESIS). J Affect Disord 81: 231–40.
Copyright © 2008 John Wiley & Sons, Ltd
139
Stansfeld S, Marmot M (1992). Deriving a survey measure
of social support: the reliability and validity of the
Close Persons Questionnaire. Soc Sci Med 35: 1027–
35.
Suh T, Gallo JJ (1997). Symptom profiles of depression
among general medical service users compared with specialty mental health service users. Psychol Med 27:
1051–63.
Sullivan PF, Neale MC, Kendler KS (2000). Genetic epidemiology of major depression: review and meta-analysis.
Am J Psychiatry 157: 1552–62.
Terluin B, van Marwijk HW, Ader HJ, de Vet HC, Penninx
BW, Hermens ML, van Boeijen CA, van Balkom AJ, van
der Klink JJ, Stalman WA (2006). The Four-Dimensional
Symptom Questionnaire (4DSQ): a validation study of a
multidimensional self-report questionnaire to assess distress, depression, anxiety and somatization. BMC Psychiatry 6: 34.
van Balkom AJ, Beekman AT, de BE, Deeg DJ, van DR, van
TW (2000). Comorbidity of the anxiety disorders in a
community-based older population in the Netherlands.
Acta Psychiatr Scand 101: 37–45.
van den Heuvel OA, Groenewegen HJ, Barkhof F, Lazeron
RH, van Dyck R, Veltman DJ (2003). Frontostriatal
system in planning complexity: a parametric functional
magnetic resonance version of Tower of London task.
Neuroimage 18: 367–74.
van der Does W (2002). Cognitive reactivity to sad mood:
structure and validity of a new measure. Behav Res Ther
40: 105–20.
Vollebergh WA, Iedema J, Bijl RV, de GR, Smit F, Ormel J
(2001). The structure and stability of common mental
disorders: the NEMESIS study. Arch Gen Psychiatry 58:
597–603.
Vollrath M, Angst J (1989). Outcome of panic and depression
in a seven-year follow-up: results of the Zurich study. Acta
Psychiatr Scand 80: 591–6.
Wacker HR, Battegay R, Mullejans R, Schlosser C (2006).
Using the CIDI-C in the general population. In Stefanis
CN, Rabavilas AD, Soldatos CR (eds) Psychiatry: A
World Perspective. Amsterdam: Elsevier Science
Publishers, pp. 138–43.
Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC,
Borges G, Bromet EJ, Bruffaerts R, de Girolamo G, de
Graaf R, Gureje O, Haro JM, Karam EG, Kessler RC,
Kovess V, Lane MC, Lee S, Levinson D, Ono Y, Petukhova
M, Posada-Villa J, Seedat S, Wells JE (2007). Use of
mental health services for anxiety, mood, and substance
disorders in 17 countries in the WHO world mental
health surveys. Lancet 370: 841–50.
Watson D, Weber K, Assenheimer JS, Clark LA, Strauss ME,
McCormick RA (1995). Testing a tripartite model: I.
Evaluating the convergent and discriminant validity of
anxiety and depression symptom scales. J Abnorm Psychol
104: 3–14.
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr
140
Penninx et al.
Wittchen HU (1994). Reliability and validity studies of
the WHO – Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res 28: 57–84.
Wittchen HU, Burke JD, Semler G, Pfister H, Von CM,
Zaudig M (1989). Recall and dating of psychiatric symptoms. Test-retest reliability of time-related symptom questions in a standardized psychiatric interview. Arch Gen
Psychiatry 46: 437–43.
Wittchen HU, Robins LN, Cottler LB, Sartorius N, Burke
JD, Regier D (1991). Cross-cultural feasibility, reliability
and sources of variance of the Composite International
Diagnostic Interview (CIDI). The multicentre
WHO/ADAMHA field trials. Br J Psychiatry 159: 645–53,
658.
Copyright © 2008 John Wiley & Sons, Ltd
Wust S, Wolf J, Hellhammer DH, Federenko I, Schommer
N, Kirschbaum C (2000). The cortisol awakening response
– normal values and confounds. Noise Health 2000; 2:
79–88.
Correspondence: Brenda Penninx, PhD, Department of
Psychiatry, VU University Medical Centre, AJ Ernststraat
887, 1081 HL Amsterdam, The Netherlands.
Tel: +31 20 7885437
Fax: +31 20 7885664
Email: b.penninx@vumc.nl
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
DOI: 10.1002/mpr